Solaxa PBC

Solaxa is a biopharmaceutical start-up focused on improving the lives of children and adults suffering from nerve damage. Nerves control everything we feel and do, and diseases and injuries that cause damage are devastating. Dalfampridine, a small molecule drug, is already FDA approved to improve walking speed in adults with multiple sclerosis (MS). Solaxa will first develop a pediatric version of dalfampridine to treat two rare conditions; Ataxia Telangiectasia and children with MS. Solaxa also has plans to commercialize novel patented formulations of dalfampridine to treat nerve injury.